Understanding the role of PCSK9 in this context could open new avenues for predicting and preventing hyperlipidemia in T2D patients, thereby improving clinical outcomes and reducing cardiovascular risk. This evidence concerns the gene PCSK9 and type 2 diabetes mellitus.